Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PepCan for Cervical HSIL
NCT02481414Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Nov 2015
- Primary completion
- Sep 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PepCan in Squamous Intraepithelial Lesion (SIL) and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by University of Arkansas. Primary endpoints: Number of Subjects With Complete Response With the Intention-to-treat (ITT) Analysis at 15 months, Number of Subjects With Complete Response With the Per-protocol Analysis at 15 months and 2 more. Started Nov 2015; status: completed.
02
Drugs
PepCan
03
Conditions
Squamous Intraepithelial Lesion (SIL)cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02481414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481414.